We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-7.96%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$942M
Cap. Flow
-$780M
Cap. Flow %
-76.64%
Top 10 Hldgs %
36.57%
Holding
87
New
6
Increased
6
Reduced
47
Closed
24
Avg Time Held Equity + Options
1.3 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$15.3M
2
JANX icon
Janux Therapeutics
JANX
+$9.52M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.05M
4
DXCM icon
DexCom
DXCM
+$5.77M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.58M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$48.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$43.4M
3
BSX icon
Boston Scientific
BSX
+$39.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$29.6M
5
ILMN icon
Illumina
ILMN
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
2 Miscellaneous 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DNTH icon
1
Dianthus Therapeutics
DNTH
$4.17B
$62.6M 6.15%
2,873,000
-44,231
-2% -$1.14M
2023 Q3
5 quarters
BSX icon
2
Boston Scientific
BSX
$64B
$46M 4.52%
515,000
-447,000
-46% -$39.3M
2022 Q1
11 quarters
JANX icon
3
Janux Therapeutics
JANX
$1.06B
$39.7M 3.9%
741,900
+179,900
+32% +$9.52M
2024 Q1
3 quarters
NTRA icon
4
Natera
NTRA
$58.3B
$35.4M 3.48%
223,800
-332,600
-60% -$48.4M
2020 Q3
17 quarters
EXAS icon
5
DELISTED
Exact Sciences
EXAS
$33.9M 3.33%
603,011
+15,011
+3% +$934K
2024 Q2
2 quarters
ISRG icon
6
Intuitive Surgical
ISRG
$151B
$33.8M 3.32%
64,800
-83,400
-56% -$43.4M
2023 Q4
4 quarters
CGON icon
7
CG Oncology
CGON
$5.48B
$31.5M 3.09%
1,097,800
-558,200
-34% -$19.1M
2024 Q1
3 quarters
UNH icon
8
UnitedHealth
UNH
$365B
$30.4M 2.98%
60,000
-27,400
-31% -$15.6M
2024 Q3
1 quarter
NBIX icon
9
Neurocrine Biosciences
NBIX
$13.9B
$30.1M 2.95%
220,400
-239,600
-52% -$29.6M
2020 Q4
16 quarters
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.27B
$29M 2.84%
1,126,700
-246,300
-18% -$6.97M
2021 Q1
15 quarters
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$13.9B
$28.9M 2.84%
234,500
-196,500
-46% -$23.2M
2022 Q2
10 quarters
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$5.35B
$27.5M 2.71%
666,200
-64,904
-9% -$2.7M
2023 Q3
5 quarters
ACHC icon
13
Acadia Healthcare
ACHC
$2.89B
$26.1M 2.56%
658,000
-327,000
-33% -$14.7M
2022 Q2
10 quarters
ARVN icon
14
Arvinas
ARVN
$468M
$26M 2.56%
1,358,000
-139,000
-9% -$3.38M
2020 Q2
18 quarters
GKOS icon
15
Glaukos
GKOS
$9.77B
$25.5M 2.5%
170,000
-174,900
-51% -$24.1M
2024 Q1
3 quarters
DXCM icon
16
DexCom
DXCM
$33.1B
$24.7M 2.43%
318,000
+78,000
+33% +$5.77M
2024 Q1
3 quarters
TMO icon
17
Thermo Fisher Scientific
TMO
$258B
$23.2M 2.28%
44,600
-24,000
-35% -$13.2M
2023 Q4
4 quarters
HUM icon
18
Humana
HUM
$51.9B
$22.6M 2.22%
89,200
-40,500
-31% -$10.9M
2024 Q3
1 quarter
KYMR icon
19
Kymera Therapeutics
KYMR
$8.99B
$20.1M 1.98%
500,000
– –
2024 Q3
1 quarter
AVTR icon
20
Avantor
AVTR
$10.9B
$20M 1.96%
947,000
-288,000
-23% -$6.48M
2023 Q4
4 quarters
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.22B
$19.8M 1.95%
1,500,000
-955,000
-39% -$16.3M
2020 Q2
18 quarters
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$19.5M 1.92%
1,165,800
-966,200
-45% -$16M
2024 Q3
1 quarter
RVMD icon
23
Revolution Medicines
RVMD
$40.6B
$19.5M 1.92%
446,200
-343,800
-44% -$17.4M
2022 Q2
10 quarters
XENE icon
24
Xenon Pharmaceuticals
XENE
$3.32B
$18.6M 1.82%
474,000
-344,000
-42% -$14.2M
2023 Q2
6 quarters
THC icon
25
Tenet Healthcare
THC
$22.2B
$17.3M 1.7%
137,000
-116,000
-46% -$17.2M
2022 Q4
8 quarters
1
2 3 4

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q4 2024 Portfolio in Review

As of Q4 2024, Avidity Partners Management held 87 positions worth $1.02B, down 48% from $1.96B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Avidity Partners Management withdrew a net $780M in Q4 2024, closing 24 positions and reducing 47 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $5.98M.

  • Avidity Partners Management's largest Q4 2024 buy was Regeneron Pharmaceuticals: 8,400 shares worth $5.98M.
  • Avidity Partners Management added most to Transmedics in Q4 2024, an estimated $15.3M increase.
  • Avidity Partners Management's biggest Q4 2024 reduction was Natera, cutting an estimated $48.4M.
  • Avidity Partners Management fully exited BioMarin Pharmaceuticals in Q4 2024, selling an estimated $22.5M.
  • Avidity Partners Management's ten largest holdings make up 37% of its $1.02B portfolio in Q4 2024.
  • Avidity Partners Management opened 6 new positions and closed 24 in Q4 2024.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $1.02B.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.